BMS buys Mirati for $4.8B; Pfizer to slash cost; Q&A with Vertex CSO; Alnylam's Onpattro setback; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
After Mirati opened the week with a multibillion-dollar buyout, we take a look at Bristol Myers Squibb’s budding rivalry with Amgen, Pfizer’s planned cost cuts, a surprise CRL for Alnylam, a busy stream of clinical readouts and much, much more. Don’t miss our roundup of the key takeaways from our #EuroBio23 summit in London.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.